T1-44 / IngenOx Therap - LARVOL DELTA

Vactosertib combined treatment with T1-44, a PRMT5 activity inhibitor, improves the survival and inhibits tumor invasion of murine pancreatic cancer model (AACR 2023) - "RNA sequencing analysis of mouse tumors revealed that the combination of T1-44 and vactosertib significantly altered the expression of genes involved in cancer progression, such as cell migration, extracellular matrix, and apoptotic processes. These data demonstrate that the combination therapy of T1-44 with vactosertib is synergistic for pancreatic cancer, suggesting that this novel combination therapy has value in the treatment strategy of patients with pancreatic cancer."

Preclinical • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor • PRMT5 • TGFB1

"K-Bio, pre-clinical presentation at AACR… targeting the global market" (HIT News) - "ABL Bio will present the preclinical data of ABL102 (ROR1x4-1BB), a candidate for immuno-anticancer drug, as a poster at the American Association for Cancer Research (AACR)....Medpacto...announced that the preclinical data of Vactosertib combination therapy for pancreatic cancer was adopted as a poster at the American Association for Cancer Research (AACR 2023). Medpacto will disclose preclinical data of the combination therapy of Vactosertib and T1-44, a protein activity inhibitor of arginine methyltransferase 5 (PRMT5), in this conference. PRMT5 protein, known as an enzyme that promotes cancer growth, is known to increase its expression in various cancers including pancreatic cancer."

Preclinical • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor